Bioresearch Online News

Novavax Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy Adults

Mon, 08 Feb 2010 07:16:00 GMT

Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine.

Lupin Receives FDA Approval For Amlodipine/Benazepril Capsules

Mon, 08 Feb 2010 06:05:00 GMT

Lupin Pharmaceuticals, Inc. announced recently that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules.

Novozymes Signs Agreement With ProMetic For Albumin Purification Technology

Fri, 05 Feb 2010 06:15:00 GMT

Novozymes A/S, a Denmark-based biotechnology company, and ProMetic Life Sciences, Inc., a Canada-based biopharmaceutical company, have entered into a strategic agreement regarding proprietary albumin purification technology based upon a synthetic-ligand affinity adsorbent developed by ProMetic's UK subsidiary, ProMetic BioSciences, Ltd.

Calibration Free Supersaturation Assessment and Control For The Development And Optimization of Crystallization Processes

Thu, 04 Feb 2010 14:24:00 GMT

In this webinar, a method will be presented which facilitates the calibration free use of in situ ATR-FTIR spectra for the production and control of qualitative supersaturation trajectories.

Mirrx Therapeutics A/S Secures Seed Financing For Development Of Novel MicroRNA-Blocking Technology

Thu, 04 Feb 2010 14:17:35 GMT

Mirrx Therapeutics today announced that it has closed on a seed financing round that will enable the company to achieve in vivo proof of concept for its microRNA-blocking "Blockmir" technology, as well as to strengthen its intellectual property portfolio.

$4.25 Million For HIV Research In Geneva

Thu, 04 Feb 2010 09:56:00 GMT

The Mintaka Foundation for Medical Research in Geneva announced today that the Wellcome Trust, London, has awarded it approximately CHF 4,500,000 to meet the remaining costs of bringing its flagship product, an anti-HIV microbicide known as 5P12-RANTES, to a first safety trial in the clinic.

Infosys Technologies And Elan Pharmaceuticals Apply Co-Creation Model To Transform Discovery Research

Thu, 04 Feb 2010 08:37:00 GMT

Infosys Technologies Limited (Nasdaq: INFY) today announced that it will design and implement the Research Informatics System (RISe) at Elan Pharmaceuticals, Inc (NYSE: ELN), a leading biotechnology company, to accelerate discovery research using a path-breaking co-creation engagement model that leverages Infosys' existing intellectual property in this field.

GSK Launches New Specialist Unit To Research And Develop Medicines For Rare Diseases

Thu, 04 Feb 2010 06:10:00 GMT

GSK recently announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.

Gorbec Pharmaceutical Services, Inc. Announces The Launch Of Its GMP Analytical Laboratory In China

Thu, 04 Feb 2010 06:03:00 GMT

Gorbec Pharmaceutical Services, a rapidly expanding contract developer and manufacturer of prescription pharmaceutical products, is opening a GMP-compliant analytical laboratory in Yantai, China.

Access Pharmaceuticals Initiates Program Applying Cobalamin Platform To siRNA Drug Delivery

Thu, 04 Feb 2010 05:53:00 GMT

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies.

Thermo Fisher Scientific Introduces Chromatography Pipette Tips

Thu, 04 Feb 2010 05:30:00 GMT

Thermo Fisher Scientific Inc., the world leader in serving science, recently announced the availability of the new Thermo Scientific Aspire Protein A, Protein G and IMAC Cobalt Chromatography Tips.

New Brunswick's New Mobile Pilot Plant Fermentor Offers Flexibility And Portability

Thu, 04 Feb 2010 04:48:00 GMT

New Brunswick Scientific's new BioFlo® 610 Mobile Pilot Plant Fermentor is exceptionally compact and versatile.

IATA Chapter 17 Revised Regulations And Biopharma Requirements For Temperature-Sensitive Products Discussion

Wed, 03 Feb 2010 16:02:00 GMT

Pharma IQ, a division of IQPC, announces that Kevin O'Donnell Director & CTA of Tegrant Corporation and Chair of IATA's Time & Temperature Task Force will discuss compliance with IATA's revised Chapter 17 at the 8th Cold Chain Management and Temperature Control Summit.

Lab901 Announces True At-Line Monitoring Of Monoclonal Antibody Production By SDS-PAGE

Wed, 03 Feb 2010 04:54:00 GMT

Lab901 announced at the Peptalk 2010 conference that its Protein ScreenTape®platform can deliver, for the first time, true, practical at-line monitoring of monoclonal antibody production.

clinicalprojects International GmbH Announces Further Growth Into New Therapeutic And Geographic Areas

Wed, 03 Feb 2010 04:27:00 GMT

clinicalprojects international GmbH (CPI), an independent contract research organization, announced today that the company is continuing its growth into new therapeutic areas for the development of (bio)pharmaceuticals and medical devices.

Pall Corporation Introduces The PallSep Biotech Filtration System For Difficult-To-Process Biotechnology Feed Streams

Tue, 02 Feb 2010 21:31:00 GMT

Pall Corporation, a global leader in filtration, separation and purification, has introduced the PallSep Biotech system for the gentle separation of target molecules from complex biotechnology process fluids.

Electrical Sensing Zone Particle Size/Particle Count Webinar Tomorrow

Tue, 02 Feb 2010 21:14:52 GMT

The first in a series of Micromeritics technical presentations will cover the Elzone electrical sensing zone particle size/count technique and its pharmaceutical applications with a live webinar on Thursday, February 4 at 11 AM EST.

Novozymes And ProMetic Enter Into Alliance For Purification Of Albumin-Fusion Proteins

Tue, 02 Feb 2010 20:30:50 GMT

Novozymes (OMX: NZYM B) ("Novozymes") and ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that they have entered into a strategic alliance regarding proprietary albumin purification technology based upon a synthetic-ligand affinity adsorbent developed by ProMetic's UK subsidiary, ProMetic BioSciences Ltd. The purification technology has been designed for the rapid and cost-effective development of Novozymes' albufuse� albumin-fusion molecules.

HIV Researchers Solve Key Puzzle After 20 Years Of Trying

Tue, 02 Feb 2010 20:19:12 GMT

The researchers, from Imperial College London and Harvard University, have grown a crystal that reveals the structure of an enzyme called integrase, which is found in retroviruses like HIV. When HIV infects someone, it uses integrase to paste a copy of its genetic information into their DNA.

Stem Cell And ALS Therapy Development Institute Extend Their Collaboration To Advance Potential Stem Cell Assisted Therapy For ALS

Tue, 02 Feb 2010 20:05:30 GMT

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis).